Hereditary Angioedema - Market Insights, Epidemiology and Market Forecast - 2025 - Product Image

Hereditary Angioedema - Market Insights, Epidemiology and Market Forecast - 2025

  • ID: 4401831
  • Drug Pipelines
  • Region: Global
  • 99 Pages
  • DelveInsight
1 of 4
Covers the Therapeutics Market Revenue, Treatment Practice/Algorithm and Forecasted Market Size of Hereditary Angioedema from 2017 to 2025 Segmented by Seven Major Markets

FEATURED COMPANIES

  • And others
  • BioCryst Pharmaceuticals
  • CSL Behring
  • Pharming Technologies
  • Shire
  • MORE
Hereditary Angioedema - Market Insights, Epidemiology and Market Forecast-2025 provides an overview of the Hereditary Angioedema, epidemiology and market trend for the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Hereditary Angioedema from 2017 to 2025 segmented by seven major markets. In addition, the report also includes the forecasted epidemiology of Hereditary Angioedema till 2025. The report also covers market drivers, market barriers and unmet medical need.

This report provides the subtype specific prevalent population i.e. Type I (HAE-I), Type II (HAE-II) and Type III (HAE with Normal C1-INH). According to research, the prevalent population of Hereditary Angioedema is expected to reach up to XXX cases by the end of 2025 at a CAGR of 0.59% from 2015-2025. High prevalent cases were observed in United States as compared to EU5 and Japan.

Increase in the drugs under pipeline for HAE screening tests is one of the major drivers for the Hereditary Angioedema therapeutics market globally. There is continuous market increase for HAE due to Shire's product, which is currently dominating in HAE market with the leading treatment for both the long-term prophylaxis (Cinryze), and the Acute Setting (Firazyr).

United States contributes the major share of Hereditary Angioedema market as compared to EU5 countries and Japan. The therapeutic market of Hereditary Angioedema in 7MM is expected to reach USD 2.8 Billion in 2025 at the CAGR of XX% from 2015-2025.

Key Coverage and Benefits:
  • The report will help in developing business strategies by understanding the trends shaping and driving the global Hereditary Angioedema market.
  • Organize sales and marketing efforts by identifying the best opportunities for Hereditary Angioedema in US, European Union 5 (EU5 - Germany, Spain, Italy, France and United Kingdom) and Japan.
  • To understand the future market competition in the Hereditary Angioedema market and Insightful review of the key market drivers and barriers.
  • To understand the regulatory scenario in major markets.
  • The report provides historical as well as forecasted epidemiology of Hereditary Angioedema in the 7MM covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2015-2025.
  • The report also covers the detailed historical and forecasted Hereditary Angioedema market covering United States, European Union 5 (EU5 - Germany, Spain, Italy, France and United Kingdom) and Japan from 2015-2025.
Note: Please allow up to 24 hours for delivery after payment has been made.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • And others
  • BioCryst Pharmaceuticals
  • CSL Behring
  • Pharming Technologies
  • Shire
  • MORE
1. Report Introduction

2. Hereditary Angioedema Market Overview at a Glance: Global (2015-2025)
2.1. Total Market Share Distribution of Hereditary Angioedema for 7 MM in 2016
2.2. Total Market Share Distribution of Hereditary Angioedema for 7 MM in 2025

3. Hereditary Angioedema (HAE)
3.1. Overview
3.2. Types of Hereditary Angioedema (HAE)
3.3. Symptoms
3.4. Pathophysiology
3.5. Diagnosis
3.6. Diagnostic Algorithm
3.7. Treatment
3.8. Prophylaxis Algorithm

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total number of Prevalent cases - 7MM Countries - (2016 & 2025)
4.3. Total number of Prevalent cases - Region wise - (2016 & 2025)
4.4. Distribution of Prevalent cases - 7MM Countries - (2016)

5. United States
5.1. Prevalent Cases of Hereditary Angioedema in United States
5.2. Distribution of Hereditary Angioedema - By Types
5.3. Prevalent Cases of Hereditary Angioedema - By Type

6. Germany
6.1. Prevalent Cases of Hereditary Angioedema in Germany
6.2. Distribution of Hereditary Angioedema - By Types
6.3. Prevalent Cases of Hereditary Angioedema - By Type

7. France
7.1. Prevalent Cases of Hereditary Angioedema in France
7.2. Distribution of Hereditary Angioedema - By Types
7.3. Prevalent Cases of Hereditary Angioedema - By Type

8. United Kingdom
8.1. Prevalent Cases of Hereditary Angioedema in United Kingdom
8.2. Distribution of Hereditary Angioedema - By Types
8.3. Prevalent Cases of Hereditary Angioedema - By Type

9. Spain
9.1. Prevalent Cases of Hereditary Angioedema in Spain
9.2. Distribution of Hereditary Angioedema - By Types
9.3. Prevalent Cases of Hereditary Angioedema - By Type

10. Italy
10.1. Prevalent Cases of Hereditary Angioedema in Italy
10.2. Distribution of Hereditary Angioedema by Types
10.3. Prevalent Cases of Hereditary Angioedema in by type - Italy

11. Japan
11.1. Prevalent Cases of Hereditary Angioedema in Japan
11.2. Distribution of Hereditary Angioedema by Types
11.3. Prevalent Cases of Hereditary Angioedema in by type - Japan

12. Emerging Therapies

13. SHP643
13.1. Product Profile
13.2. Clinical Development
13.3. Clinical Pipeline Activity
13.4. Ongoing Trials Information
13.5. Clinical Trial by Phase

14. Phase II

15. BCX7353
15.1. Product Profile
15.2. Clinical Development
15.3. Clinical Pipeline Activity
15.4. Ongoing Trials Information
15.5. Clinical Trial by Phase

16. Ruconest
16.1. Product Profile
16.2. Clinical Development
16.3. Clinical Pipeline Activity
16.4. Ongoing Trials Information
16.5. Clinical Trial by Phase

17. Kalbitor
17.1. Product Profile
17.2. Clinical Pipeline Activity
17.3. Ongoing Trials Information
17.4. Clinical Trial by Phase

18. Marketed Drugs for Hereditary Angioedema

19. Berinert: CSL Behring GmbH
19.1. Drug Description
19.2. Regulatory Milestones
19.3. Advantages & Disadvantages
19.4. Safety and Efficacy of Berinert
19.5. Product Profile

20. Cinryze: Shire
20.1. Drug Description
20.2. Regulatory Milestones
20.3. Advantages & Disadvantages
20.4. Safety and Efficacy of Cinryze
20.5. Product Profile

21. Ruconest: Pharming Technologies
21.1. Drug Description
21.2. Regulatory Milestones
21.3. Advantages & Disadvantages
21.4. Safety and Efficacy of Ruconest
21.5. Product Profile

22. Kalbitor: Shire
22.1. Drug Description
22.2. Regulatory Milestones
22.3. Advantages & Disadvantages
22.4. Safety and Efficacy of Kalbitor
22.5. Product Profile

23. Firazyr: Shire
23.1. Drug Description
23.2. Regulatory Milestones
23.3. Advantages & Disadvantages
23.4. Safety and Efficacy of Firazyr
23.5. Product Profile

24. Haegarda: CSL Behring
24.1. Drug Description
24.2. Regulatory Milestones
24.3. Advantages & Disadvantages
24.4. Safety and Efficacy of Firazyr
24.5. Product Profile

25. Hereditary Angioedema Market Overview: 7MM
25.1. Overview on Total Hereditary Angioedema Market (2016 & 2025)
25.2. 7MM Hereditary Angioedema Market size (2016)
25.3. 7MM Hereditary Angioedema Market size (2025)
25.4. Global Hereditary Angioedema: Market Analysis

26. United States Market Size

27. Europe Market Size
27.1. Germany Market Size
27.2. France Market Size
27.3. United Kingdom Market Size
27.4. Spain Market Size
27.5. Italy Market Size

28. Japan Market Size

29. Market Drivers

30. Market Barriers

31. Report Methodology

32. Consulting Services

33. Disclaimer

34. About

List of Tables
Table 1: Global Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Table 2: Total number of Hereditary Angioedema patient - 7MM (2016)
Table 3: Total number of Hereditary Angioedema patient - Region wise (2016 & 2025)
Table 4: Distribution of Prevalent cases - 7MM Countries - (2016)
Table 5: Prevalent Cases Hereditary Angioedema in United States (2015-2025)
Table 6: Percentage Distribution of Hereditary Angioedema by Types in United States (2016)
Table 7: Prevalent Cases of Hereditary Angioedema in United States by type (2015-2025)
Table 8: Prevalent Cases Hereditary Angioedema in Germany (2015-2025)
Table 9: Distribution of Hereditary Angioedema by Types in Germany (2016)
Table 10: Prevalent Cases of Hereditary Angioedema in Germany by type (2015-2025)
Table 11: Prevalent Cases Hereditary Angioedema in France (2015-2025)
Table 12: Distribution of Hereditary Angioedema by Types in France (2016)
Table 13: Prevalent Cases of Hereditary Angioedema in France by type (2015-2025)
Table 14: Prevalent Cases Hereditary Angioedema in United Kingdom (2015-2025)
Table 15: Distribution of Hereditary Angioedema by Types in United Kingdom (2016)
Table 16: Prevalent Cases of Hereditary Angioedema in United Kingdom by type (2015-2025)
Table 17: Prevalent Cases Hereditary Angioedema in Spain (2015-2025)
Table 18: Distribution of Hereditary Angioedema by Types in Spain (2016)
Table 19: Prevalent Cases of Hereditary Angioedema in Spain by type (2015-2025)
Table 20: Prevalent Cases Hereditary Angioedema in Italy (2015-2025)
Table 21: Distribution of Hereditary Angioedema by Types in Italy (2016)
Table 22: Prevalent Cases of Hereditary Angioedema in Italy by type (2015-2025)
Table 23: Prevalent Cases Hereditary Angioedema in Japan (2015-2025)
Table 24: Distribution of Hereditary Angioedema by Types in Japan (2016)
Table 25: Prevalent Cases of Hereditary Angioedema in Japan by type (2015-2025)
Table 26: SHP643, Clinical Trials by Zone, 2017
Table 27: Clinical Trials by Trial status, 2017
Table 28: BCX7353, Clinical Trials by Zone, 2017
Table 29: Clinical Trials by Trial status, 2017
Table 30: Ruconest, Clinical Trials by Zone, 2017
Table 31: Clinical Trials by Trial status, 2017
Table 32: Kalbitor, Clinical Trials by Zone, 2017
Table 33: Clinical Trials by Trial status, 2017
Table 34: 7 MM Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Table 35: 7 Major Market Size of Hereditary Angioedema in USD Million, (2016 & 2025)
Table 36: 7 Major Market Size of Hereditary Angioedema Market, USD Million (2016)
Table 37: 7 Major Market Size of Hereditary Angioedema Market, USD Million (2025)
Table 38: United States Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Table 39: Germany Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Table 40: France Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Table 41: United Kingdom Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Table 42: Spain Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Table 43: Italy Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Table 44: Japan Market Size of Hereditary Angioedema in USD Million, (2015-2025)

List of Figures
Figure 1: Types of Hereditary Angioedema (HAE)
Figure 2: Pathophysiology of Hereditary Angioedema
Figure 3: Prevalent Cases of Hereditary Angioedema in United States (2015-2025)
Figure 4: Percentage Distribution of Hereditary Angioedema by Types in United States (2016)
Figure 5: Prevalent Cases of Hereditary Angioedema in United States by type (2015-2025)
Figure 6: Prevalent Cases of Hereditary Angioedema in Germany (2015-2025)
Figure 7: Distribution of Hereditary Angioedema by Types in Germany (2016)
Figure 8: Prevalent Cases of Hereditary Angioedema in Germany by type (2015-2025)
Figure 9: Prevalent Cases of Hereditary Angioedema in France (2015-2025)
Figure 10: Distribution of Hereditary Angioedema by Types in France (2016)
Figure 11: Prevalent Cases of Hereditary Angioedema in France by type (2015-2025)
Figure 12: Prevalent Cases of Hereditary Angioedema in United Kingdom (2015-2025)
Figure 13: Distribution of Hereditary Angioedema by Types in United Kingdom (2016)
Figure 14: Prevalent Cases of Hereditary Angioedema in United Kingdom by type (2015-2025)
Figure 15: Prevalent Cases of Hereditary Angioedema in Spain (2015-2025)
Figure 16: Distribution of Hereditary Angioedema by Types in Spain (2016)
Figure 17: Prevalent Cases of Hereditary Angioedema in Spain by type (2015-2025)
Figure 18: Prevalent Cases of Hereditary Angioedema in Italy (2015-2025)
Figure 19: Distribution of Hereditary Angioedema by Types in Italy (2016)
Figure 20: Prevalent Cases of Hereditary Angioedema in Italy by type (2015-2025)
Figure 21: Prevalent Cases of Hereditary Angioedema in Japan (2015-2025)
Figure 22: Distribution of Hereditary Angioedema by Types in Japan (2016)
Figure 23: Prevalent Cases of Hereditary Angioedema in Japan by type (2015-2025)
Figure 24: SHP643, Clinical Trials by Zone (%), 2017
Figure 25: SHP643, Clinical Trials by Trial status (%), 2017
Figure 26: BCX7353, Clinical Trials by Zone (%), 2017
Figure 27: BCX7353, Clinical Trials by Trial status (%), 2017
Figure 28: Ruconest, Clinical Trials by Zone (%), 2017
Figure 29: Ruconest, Clinical Trials by Trial status (%), 2017
Figure 30: Kalbitor, Clinical Trials by Zone (%), 2017
Figure 31: Kalbitor, Clinical Trials by Trial status (%), 2017
Figure 32: 7 Major Market Size of Hereditary Angioedema in USD Million, (2016 & 2025)
Figure 33: 7 Major Market Size of Hereditary Angioedema Market, USD Million (2016)
Figure 34: 7 Major Market Size of Hereditary Angioedema Market, USD Million (2025)
Figure 35: United States Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Figure 36: Germany Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Figure 37: France Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Figure 38: United Kingdom Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Figure 39: Spain Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Figure 40: Italy Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Figure 41: Japan Market Size of Hereditary Angioedema in USD Million, (2015-2025)
Figure 42: Market Drivers for Hereditary Angioedema
Figure 43: Market Barriers for Hereditary Angioedema
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • CSL Behring
  • Pharming Technologies
  • Shire
  • BioCryst Pharmaceuticals
  • And others
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll